OCT 05, 2018 9:00 AM PDT

FDA approves a new drug for an advanced type of skin cancer

WRITTEN BY: Heba El Wassef

As cancer is one of the most challenging diseases in our world, many efforts have been put into researching new ways for treatment to find new drugs that could help more patients worldwide. Anticancer immunotherapy drugs are one class of drugs that have been developed recently and that have successfully helped in treating different types of cancers, no wonder that the Nobel prize in medicine/physiology this year has been awarded to the two doctors who contributed in discovering this class. 

Using PD-1/PD-L1 against cancer in immunotherapy, Credit: abcam

Recently the U.S. Food and Drug Administration has approved a new drug called Libtayo (cemiplimab-rwlc) which is a member of the anticancer immunotherapy class of drugs, it is an injection for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who cannot be treated with surgery or radiation.

This drug is the first and only drug to treat this type of skin cancer (CSCC) which is the second most common type of cancer in the United States and represents 20% of all non-melanoma skin cancer. It is usually developed by regular exposure to the sun or ultraviolet radiation. It can cause disfigurement and other local complications as bleeding or infection. Also, it can metastasize to other organs in the body which can make it life-threatening.

Libtayo works by blocking the PD-1 / PD-L1 pathway, by doing this it can help the immune system fights cancer.

The PD-1 is a protein receptor expressed on T-cells, it binds to its ligand PD-L1 which is commonly expressed on macrophages and dendritic cells. They both belong to the family of checkpoints that function to ensure that the immune system only reacts at the right time.

Cancer cells express a PD-L1 receptor that after binding to PD-1, this inhibits T cells making them unable to destroy the cancer cells and they keep on growing.

Two open-label clinical trials were done to study the efficacy and safety of Libtayo with 108 patients included (75 with metastatic disease and 33 with the locally-advanced disease). The results showed that the tumors shrunk or disappeared in 47.2% of all patients treated.

Libtayo side effects include fatigue, rash, and diarrhea. It can also cause severe or life-threatening side effects due to its effect on normal tissues and organs that can impair their functions, like lung problems (pneumonitis), intestinal problems (colitis), liver problems (hepatitis), hormone gland problems (endocrinopathies), skin (dermatologic) problems and kidney problems. Patients should also be monitored for infusion-related reactions.

It is not safe in pregnancy as it can cause harm to the fetus.

“We are continuing to see a shift in oncology toward identifying and developing drugs aimed at a specific molecular target. With the Libtayo approval, the FDA has approved six immune checkpoint inhibitors targeting the PD-1 / PD-L1 pathway for treating a variety of tumors, from bladder to head and neck cancer, and now advanced CSCC,” said Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “This type of cancer can be difficult to treat effectively when it is advanced, and it is important that we continue to bring new treatment options to patients.”

Watch the video below to learn more about cancer immunotherapy.

Source: FDA, abcam

About the Author
  • A master student in Biochemistry and Molecular biology with experience in Education and Research. I am passionate about scientific research and passing my knowledge to others to help them learn about the latest in science by teaching, writing and volunteering in scientific events.
You May Also Like
SEP 17, 2020
Cardiology
Can Grape Polyphenol Extracts prevent Cardiotoxicity?
SEP 17, 2020
Can Grape Polyphenol Extracts prevent Cardiotoxicity?
One of the biggest issues with chemotherapy treatments is their inherent toxicities. Most chemotherapy drugs are toxic t ...
OCT 14, 2020
Cancer
Using Plasma Scalpels with Chemotherapy Against Brain Cancer
OCT 14, 2020
Using Plasma Scalpels with Chemotherapy Against Brain Cancer
Cold atmospheric plasma is a relatively new technique that utilizes a tool that generates a sort of plasma scalpel, exce ...
OCT 14, 2020
Immunology
Self-Healing Microcapsules Make Promising Leukemia Vaccines
OCT 14, 2020
Self-Healing Microcapsules Make Promising Leukemia Vaccines
Leukemia is a cancer affecting tissues in the body that produce blood cells, including the bone marrow and the lymphatic ...
OCT 28, 2020
Cancer
Protecting the Head and Neck from Off Target Radiation
OCT 28, 2020
Protecting the Head and Neck from Off Target Radiation
Radiotherapy alone or with chemotherapy is the go-to treatment for head and neck cancers. Unfortunately, head and neck t ...
OCT 26, 2020
Cancer
Attacking leukemia trojan horse style
OCT 26, 2020
Attacking leukemia trojan horse style
Researchers from the Max Planck Institute of Biochemistry have developed a new approach to targeting leukemic stem cells ...
NOV 09, 2020
Cancer
A Prognostic Expression Profile for Osteosarcoma
NOV 09, 2020
A Prognostic Expression Profile for Osteosarcoma
Tireless research goes into every cancer diagnostic tools and new therapy. Many types of cancer have made giant steps fo ...
Loading Comments...